{"name":"TransThera Sciences (Nanjing), Inc.","slug":"transthera-sciences-nanjing-inc","ticker":"","exchange":"","domain":"transtherasciencesnanjing.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TT-00420 (tinengotinib)","genericName":"TT-00420 (tinengotinib)","slug":"tt-00420-tinengotinib","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"TT-00420 (tinengotinib)","genericName":"TT-00420 (tinengotinib)","slug":"tt-00420-tinengotinib","phase":"phase_3","mechanism":"Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNMlhhYUg4N0NMZXRlcnc0cFRrZ1VRLWxiYkVrVFc2aXFMcExnd3JpZUE5M1RGY01kd2E5QXVSZXdkV3dKdnpUTmxGNGp5bmhKVDdEa3d6NkZkNmlZMGFJMUVKVVNTR2d3LWtCdWJEZTlwUmc4OTRnazRLVzVrOTVOS2pjdUFiSnBwUGJxLW1xVnFwSDJ1aFRqMVBVeU84b3VLaDJnRldMMlAxaUFKV3NGcHN2eW83V0ZPa0lOVFZJdVNrQ2puTjZERTZUT2YweUVvOVdDN1FHb1FaWUo4SkVfYktDWEIxUk55WmdvNlB5YmlxNkp5TGpTMVJZTjNPZw?oc=5","date":"2026-03-19","type":"trial","source":"minichart.com.sg","summary":"TransThera Sciences Doses First Patient in Phase II Trial of Tinengotinib and Fulvestrant for HR+/HER2- Metastatic Breast Cancer 1 - minichart.com.sg","headline":"TransThera Sciences Doses First Patient in Phase II Trial of Tinengotinib and Fulvestrant for HR+/HER2- Metastatic Breas","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONnZxbjYyVVdKa1cxQlFkS2ZtV05URjFtRUdoa1BwS2I1NllYbzc2SHg2Um1nTzhFb19JZjNINy1WSlBwVnVVYV8tR0dnaHdfZG9sQkFyeTVXc1A2dVZBWmthTlh2N2c5Z0tiLVBGMHU1Zi05QUR2WDdvUHFaZlBXWTdqQUhPWGtTUlplLTBuSGxIRTRlWWFoMDZhR1FIc1lCQndvSnRodm1HUjA?oc=5","date":"2025-11-03","type":"deal","source":"Fierce Biotech","summary":"Neurocrine pens $880M deal with China's TransThera for red-hot immunology target - Fierce Biotech","headline":"Neurocrine pens $880M deal with China's TransThera for red-hot immunology target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNbm5FWTZ3a0VQdUExeDMxX2FwREo1RjlMX3I5N0RwYXJUTlZ1VU5PY2Nkcm5BVTRkOVBNQmN0bUZBQklPX2lBSUE2aS1jSWhBOExoemt6eV9HZ1N1cTZIZi05b25IOGpwY1E1Q2ZPaE0yaDEtQjdoaGpyYjUwMUF5eUJlejBpU1E?oc=5","date":"2025-09-25","type":"pipeline","source":"thebambooworks.com","summary":"A wild ride for TransThera investors: what’s the story? - thebambooworks.com","headline":"A wild ride for TransThera investors: what’s the story?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOSWJ1cWVHRVBzcGRCWnR2M3pYSWdSekt6ZjhLVG90R1EyNkNEalRZY2V4SWVLeWNJSF94YWp1YTFrdXdvT2R0YkNIRWdHYUNORXdTVGNOSkhiNnY0MzNrY2QxWVhSdWlZWkNtYklhOHI3NFBJMU5obWNiUWVWa0VWZ211Mml4V2dWZEgtMHRoZXlnVjJlY0FVd1I0Ql9TV1ZQYkNXXzBiV2JzV2pmN1hGLUJhZGE?oc=5","date":"2025-09-15","type":"pipeline","source":"Bloomberg.com","summary":"Chinese Biotech Stock’s 4,500% Surge Sparks Fear of Market Froth - Bloomberg.com","headline":"Chinese Biotech Stock’s 4,500% Surge Sparks Fear of Market Froth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQejVOQWEzZlFvQV9sYlB3ZkpsbC1MdVk2aDBLa2gxOVF2S3RiT0dHUURIOWc3VVUzWGgyNHVOUVFfVW5WYmdiNlYtdVp0M2k3M25Rb2JldERDQTZnVGhiSUZveDlGOGRRdVB4cHhIRWNwXzRtU0YyeHlZWW5YeHB3WjBwWVhBY1pWT09oek1heGhzNnVuMHVibGl6Vy03YUk?oc=5","date":"2025-09-09","type":"pipeline","source":"BioWorld News","summary":"Biopharma IPO activity slows, but 2025 returns are surging - BioWorld News","headline":"Biopharma IPO activity slows, but 2025 returns are surging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE81dnJyNUpieWprYzRlTjhtSl9yRUhZZXRXaVJrTzBKYTE1dS15Q0lLSnZpT0dTZFpBaUtjMTRkVzZ5b3dUOWZ4MDdEOV9yTU1WVDlDVHBR?oc=5","date":"2025-07-09","type":"pipeline","source":"Yahoo! Finance Canada","summary":"TransThera Sciences (Nanjing), Inc. (2617.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"TransThera Sciences (Nanjing), Inc. (2617.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQbTBYUFotVDBCU2ZNSEhqc0Y4VUkwS2t1UmR3MnNibXBWSWdJTWNuUGJWajBoNHllRzA2blJ6UEk0QWRVUEFVeDVfM3JkdEZ3Vk5lYVAwOVFkQmt6WUdxeEt5VHBvV3BVVXpFc3l2dFc2WGlFeTZ2aXF4b2I2anNiRVNsVnI4cndqczd3dG1FSC1yLU9fUTI3WmxkekdtOFh4d1MxSQ?oc=5","date":"2025-06-24","type":"pipeline","source":"BioWorld News","summary":"Transthera raises $25M with Hong Kong IPO; stock up 78% on debut - BioWorld News","headline":"Transthera raises $25M with Hong Kong IPO; stock up 78% on debut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPYXhsaGlINzdXWHZFOGFrMWMtZUp1NndKbTFEOGNlb0tlZUlieXNSaHNyb2swUk5MWWJRUkRBMjdJLXpOd0NXblNSTTIxWURKT1JJTm1fMVVxel9UMnRjNUhJc3E4TkFpS3lEcEpLcUNhbTV2eVdXSzJKZTNkQ3YzaUFkUDQyTk1NbG5KaXBiSU9nQ1JH?oc=5","date":"2024-07-18","type":"pipeline","source":"thebambooworks.com","summary":"TransThera seeks Hong Kong IPO to sustain cancer drug research - thebambooworks.com","headline":"TransThera seeks Hong Kong IPO to sustain cancer drug research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxQM1doTXIzTWFjNHFUQUxJNTdmVmlfZ2dvNGlmUndMeWN5bXlKMFg2aEtpdl8xZHBrTkFGOF82VnFTUWNnRnRPM0tzQ0hGZTZDMEppb2ozcTNLU1FiY3BZazBYQkFhaFJNRWhBXzA1Z2dkRWZZZXZLUkRneWIxbzBSOEJyUWFsWGp1QXFqaVZjUlNuWWp0cEFQQkNFTTY5R0lueTRndDQ5MFlRX2lpS2N3WUc2Z0ZYaXN3YVJmWXU3cC1hd3hHTXRPMmJ5X0lGVGpKVmY0Vkp4TFhGcmxpMnoxZHhiTUhVdFlyZUViT1lzTTNDV05FdEhYQW1MTDVpOXJNR2d2OU1fbGpKZXlIRWhLcFdVWE9WTERxa0NiWTU0R3Vvdm5wclE1MUVhclE5S28?oc=5","date":"2020-08-17","type":"deal","source":"Business Wire","summary":"LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions - Business Wire","headline":"LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Ch","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}